NSE · INFLUX
Influx Healthtech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹148 Cr with net profit ₹21 Cr — a 13.86% net margin, versus 12.73% the period before.
Shareholding
As of 2026-03-31
- Promoter73.53%
- Public20.66%
- FII0.16%
- DII5.65%
1,335 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.87× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 51 by market cap · medians across 44 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,73,067 Cr | 77.57 | 9.46 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹46,927 Cr | 40.95 | 4.53 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹42,249 Cr | 37.23 | 9.4 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹24,669 Cr | 85.6 | 19.2 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹17,618 Cr | 61.95 | 6.8 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹17,284 Cr | 25.98 | 5.12 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹15,333 Cr | 23.35 | 3.7 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,443 Cr | 26.02 | 4.45 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,596 Cr | 47.92 | 5.5 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹5,736 Cr | 45.39 | 6.15 | 12.36% | 18.59% |
| Influx Healthtech Limited(this company) | — | 29 | 5.91 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashInflux Healthtech Limited, operating in the Pharmaceuticals sector, has a book value of Rs 43.52 and earnings per share (EPS) of Rs 8.87. The company's ROCE is 59.59% and its debt-to-equity ratio is 0.01. The P/E ratio stands at 32.71.
Positives
- +The debt-to-equity ratio is low at 0.01, indicating conservative financial management.
- +Promoter holding is strong at 73.5342% as of March 31, 2026.
- +The company's ROCE is 59.59%, suggesting efficient capital utilization.
- +Revenue increased from Rs 0 Cr in Mar 2021 to Rs 104.9868 Cr in Mar 2025.
- +Net profit increased from -Rs 0.004382 Cr in Mar 2021 to Rs 13.366 Cr in Mar 2025.
Negatives
- −No quarterly results have been disclosed since March 2026.
- −The number of shareholders decreased from 2404 in Jun 2025 to 1335 in Mar 2026.
- −FII holding decreased from 3.3848% in Jun 2025 to 0.1633% in Mar 2026.
Financial Performance
Influx Healthtech Limited reported revenue of Rs 104.9868 Cr in Mar 2025, an increase from Rs 100.016 Cr in Mar 2024. Net profit also rose to Rs 13.366 Cr in Mar 2025 from Rs 11.128 Cr in Mar 2024. The company's EPS increased to Rs 7.36 in Mar 2025 from Rs 6.13 in Mar 2024.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing. The book value per share is Rs 43.52.
Profitability & Returns
Influx Healthtech Limited's Return on Capital Employed (ROCE) is 59.59%, suggesting efficient use of capital in generating profits. The earnings per share (EPS) for the latest period is Rs 8.87.
Ownership & Pledges
As of March 31, 2026, promoters held 73.5342% of the shares, while public shareholding was 20.6551%. DIIs held 5.6474% and FIIs held 0.1633%. There are no reported promoter share pledges.
Data as of — price: 2026-10-27 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.